Daclizumab HYP in Relapsing–Remitting MS

Daclizumab is a humanized monoclonal antibody that targets CD25, the high-affinity interleukin-2 receptor IL2R on lymphocytes. It is FDA approved for use in organ transplantation. These researchers conducted a multicenter, dose-ranging, manufacturer-funded, 1-year trial of high-yield process (HYP) daclizumab for relapsing–remitting multiple sclerosis (MS). Daclizumab HYP differs from other formulations of daclizumab in its glycosylation profile, which leads to less antibody-dependent cellular cytotoxicity activity. They randomized 621 patients in a 1:1:1 ratio to subcutaneous daclizumab 150 mg, subcutaneous daclizumab 300 mg, or placebo once per week for 52 weeks. The primary endpoint was the annualized relapse rate at week 52. Secondary en…